Hypervision Surgical Raises GBP 17M Series A for AI-Powered Surgical Imaging

Funding Overview

Hypervision Surgical, a King's College London spin-out, closed a GBP 17 million Series A funding round to advance its AI-powered hyperspectral imaging platform for real-time surgical decision-making. The company's Hyperspectral Intelligence technology provides quantitative insights into tissue health during operations—information invisible to the human eye and standard surgical cameras.

The round was led by Heal Capital, with participation from Angelini Ventures, IP Group, Daycrest, HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures. Strategic partners include SINC Fund (managed by SAGES Ingenuity) and Macmillan Cancer Support.

This funding will enable Hypervision Surgical to accelerate commercial deployment of its technology across surgical specialties and expand its AI capabilities for real-time tissue analysis.

The Surgical Visualization Challenge

Surgeons currently rely on visual cues and tactile feedback to assess tissue health during operations. However, critical information about tissue composition, oxygenation, and viability often cannot be seen with the naked eye. This limitation can lead to complications such as incomplete tumor resection or tissue damage that could have been prevented with better intraoperative information.

The challenge has been developing imaging technology that is both scientifically informative and practical for use in the operating room environment. Traditional imaging modalities like white-light endoscopy and standard camera systems provide limited information about tissue biochemistry.

Despite advances in surgical technique, complications from inadequate tissue assessment remain a significant problem. Incomplete tumor resection can lead to cancer recurrence, while unintended tissue damage can cause complications, extended hospital stays, and poor patient outcomes.

Hyperspectral Intelligence Technology

Hypervision Surgical's platform captures tissue physiology and composition data beyond human vision. The technology uses artificial intelligence to analyze this spectral data in real-time, providing quantitative insights into tissue health.

Unlike traditional imaging that captures visible light, hyperspectral imaging captures data across a broad spectrum of wavelengths, revealing information about tissue biochemistry that correlates with health status. This includes oxygenation levels, hydration, and metabolic activity.

The AI algorithms have been trained on extensive datasets of surgical images paired with clinical outcomes, enabling accurate prediction of tissue viability and tumor margins.

Key Features

• Beyond Human Vision: Captures spectral data invisible to standard cameras
• AI-Driven Analytics: Real-time quantitative tissue health analysis using machine learning
• Platform Flexibility: Designed for laparoscopic, robotic, microscopic, and endoscopic platforms
• Regulatory Clearances: FDA-cleared for open and minimally invasive general surgery; certified in the UK
• FDA Safer Technologies Program: Selected for STeP, indicating regulatory support for innovative safety technologies
• Real-Time Processing: Instantaneous analysis without requiring additional imaging time

The HYPERSNAP System

The HYPERSNAP system is built on NVIDIA IGX architecture for high-speed edge computing and real-time AI inference. This hardware-to-software shift moves surgical imaging from static hardware to a flexible, cloud-enabled, software-centric paradigm.

The platform aims to improve surgical outcomes and patient safety by giving surgeons real-time insights into tissue that were previously impossible to access during operations. The system integrates seamlessly with existing surgical workflows.

Clinical Applications

The technology has applications across multiple surgical specialties:

• Tumor margin assessment during cancer surgery
• Tissue perfusion monitoring during vascular procedures
• Nerve identification to prevent accidental damage
• Wound healing assessment
• Anastomosis verification during gastrointestinal surgery
• Cardiac tissue viability assessment

Leadership

Hypervision Surgical was co-founded by Dr. Michael Ebner, CEO, a scientist focusing on computational hyperspectral imaging at King's College London. His research has focused on developing novel imaging techniques for surgical applications.

The company is co-developing sensing technology with Imec, a global leader in semiconductor and spectral sensing. This partnership provides access to cutting-edge sensor technology.

Tanja Dowe, Managing Director of Angelini Ventures, has joined the company's Board of Directors following the funding round, bringing extensive experience in medtech commercialization.

Funding Allocation

Use of capital:

• Commercial deployment of the Hyperspectral Intelligence platform
• Clinical adoption expansion across surgical specialties
• Platform enhancement and scalable cloud-enabled AI layer development
• Regulatory clearances for additional indications
• Expansion of manufacturing capabilities

Market Opportunity

The surgical imaging market is growing as hospitals seek technologies that improve outcomes and reduce complications. With hundreds of millions of surgeries performed annually, even modest adoption represents substantial opportunity.

Key growth drivers include increasing focus on surgical quality, demand for objective data-driven decision-making, growth in minimally invasive surgery, and rising healthcare spending on surgical technology.

Hypervision's focus on AI-powered spectral analysis positions it at the intersection of surgical devices and digital health—a rapidly expanding category.

Competitive Landscape

Surgical imaging technologies include standard white-light imaging (current standard), fluorescence imaging (emerging), hyperspectral imaging (Hypervision's approach), and AI-enhanced standard imaging (computational approaches).

Hypervision's advantages include comprehensive spectral analysis, real-time processing, regulatory clearances, and established partnerships with leading healthcare institutions.

Looking Ahead

Hypervision Surgical is positioned to establish a new data-driven standard for surgical care. Success will depend on continued clinical adoption, expansion across surgical specialties, and demonstration of improved patient outcomes in broader studies.

The company plans to expand its regulatory clearances to additional surgical specialties and geographies, enabling broader patient access to its technology.

Regulatory Pathway

Hypervision Surgical has achieved significant regulatory milestones. The FDA-cleared status for open and minimally invasive general surgery represents a major accomplishment. The company is pursuing additional clearances for specialized surgical applications.

The FDA Safer Technologies Program (STeP) selection provides regulatory support and expedited review pathways. This program is designed to help bring innovative safety technologies to market faster.

Clinical Evidence

Clinical studies have demonstrated the technology's ability to differentiate healthy from diseased tissue with high accuracy. Studies across multiple surgical specialties have shown consistent results.

The technology has been validated in over 1,000 surgical procedures, providing robust evidence for its clinical utility.

Technology Integration

The platform integrates seamlessly with existing surgical infrastructure. The software-centric approach enables deployment without significant hardware modifications.

Partnerships

Strategic partnerships with Imec for sensor technology and ZEISS for optical components provide access to leading-edge technology. Macmillan Cancer Support partnership focuses on improving cancer surgery outcomes.

Revenue Model

The company generates revenue through system sales, software subscriptions, and per-procedure fees. This combination provides predictable recurring revenue.

Competitive Advantages

Unlike traditional imaging, Hypervision provides objective, quantitative data. The AI-powered analysis enables consistent interpretation across users.